New generation of obesity drugs: Promising solutions with caveats

In a world where obesity has become an epidemic, the search for effective weight loss solutions continues. However, recent developments in the pharmaceutical industry have introduced a new wave of hope for those struggling with weight management. With drugs like Ozempic, Wegovy, and Mounjaro making waves, the question arises: Are obesity drugs finally here? Here’s what you need to know.

If you’ve turned on your television lately, chances are you’ve come across commercials for Ozempic, a diabetes drug accompanied by a catchy jingle reminiscent of Pilot’s 1974 hit “Magic.” Although the onscreen text clearly states that Ozempic is not a weight loss drug, the commercial cleverly highlights its potential for weight reduction. This marketing strategy appears to be effective, as pharmacies filled more than double the number of Ozempic prescriptions during the last week of February 2023 compared to the same period in 2022.

While Ozempic cannot be directly prescribed as a weight loss aid, a higher-dose variant called Wegovy has garnered attention. Developed specifically for weight loss, Wegovy received approval from the U.S. Food and Drug Administration (FDA) last year. Additionally, Eli Lilly, the drugmaker responsible for Wegovy, is eagerly awaiting FDA approval for Mounjaro, a drug that could potentially become the most potent anti-obesity medication on the market. If granted fast-track approval, Mounjaro may revolutionize weight loss treatments.

All three drugs belong to a class known as GLP-1 receptor agonists, which mimic hormones released after eating. These hormones help regulate blood sugar levels and slow down digestion, resulting in increased feelings of fullness and reduced caloric intake. Mounjaro, in particular, targets a second hormone that Eli Lilly believes can induce even more significant weight loss. Clinical trials for Mounjaro have shown remarkable results, with participants losing up to 22 percent of their body weight, compared to a mere 3 percent in the placebo group.

Despite their potential, these obesity drugs come with their fair share of caveats. Common side effects associated with GLP-1 receptor agonists include nausea, vomiting, constipation, diarrhea, and stomach pain. Moreover, Medicare and most private insurance plans do not cover weight loss drugs, leaving patients to bear the full financial burden. The cost can amount to over $1,300 per month, making it a substantial investment for those seeking treatment. Furthermore, discontinuation of these drugs often leads to weight regain, underscoring the need for long-term commitment and lifestyle changes.

The introduction of drugs like Ozempic and Wegovy and the potential approval of Mounjaro offer a glimpse of hope for individuals battling obesity. The class of drugs known as GLP-1 receptor agonists shows promise in promoting weight loss, reducing the risks associated with obesity, and potentially revolutionizing obesity treatment. However, it is crucial to consider the potential side effects and financial implications before embarking on such a treatment. Obesity drugs might be here, but they come with important considerations that should not be overlooked.